Israel's Coronavirus drug that claims to have a 100% accuracy rate among severely infected COVID19 patients is being tested on the United States of America for the first time .

The first trial comes after Pluristem Therapeutics Inc. a biotech company based in Haifa reported on last week that seven COVID19 patients who were at a high risk of death due to respiratory failure survived after receiving the drug .

The COVID19 patients were approved for treatment under the compassionate use programme and exhibited respiratory failure requiring intubation in the ICU . Four of the COVID19 patients had multi system organ failure including kidney and heart failure .

Also read An Indian Professor has claimed to develop a major software which can detect COVID19 within 5 seconds using x-ray scan of the suspected person

The seven sufferers were treated with Pluristem's allogeneic placental expanded cells . Fundamentally these cells can potentially reverse or suppress the dangerous over activation of the immune system which causes death in many COVID19 patients .

A spokesperson told CBN news that Pluristem uses donated placentas at the time of delivery of healthy, full grown babies from healthy women under the age of 35yrs old undergoing an elective Caesarean section .

All seven of the COVID19 patients who received the medication survived and four of the patients improved in respiration .

Recently a Coronavirus patient in the United States of America has been treated with PLX cell therapy at Holy name medical center in New Jersey . The outcomes of the treatment have yet to be released .

Pluristem targets to an international clinical study on the drug to better test for it's effectiveness .

Pluristem CEO and president Yaky Yanay stated that they were pleased with the initial outcome of the compassionate use programme and committed to harnessing PLX cells for the benefit of COVID19 patients and the health care system . In order to increase PLX cells impact on COVID19 patient's recovery and to work towards making this treatment internationally available , they planned to move towards a clinical development programme .

He also told that they believe that the government and research funding should be available to Pluristem to support the use of PLX cells for patients suffering from Coronavirus .

Swayampakula Ramakanth a wall street analyst at HC Wainwright informed Yahoo News that he is very encouraged by the results .